KIR3DL1 and neoplasm: In either case, minimizing NK cell inhibition by interfering with KIR/NKG2A or any other relevant inhibitory immune checkpoint receptors, in combination with an approach to maximize NK cell activation via engagement of CD16 or a CAR may help to potentiate the NK cell anti-tumor effects which will be especially relevant for tumors with a highly suppressive TME.